Sartorius AGSARTF -1.83%85 Days Payable is 65.23 as of Mar. 2026, which is 17% below its 10-year median of 78.48. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Sartorius AG ranks worse than 51.95% on this metric.
The historical rank and industry rank for Sartorius AG's Days Payable or its related term are showing as below:
SARTF'
s Days Payable Range Over the Past 10 Years
Min: 63.76 Med: 78.48 Max: 97.52
Current: 66.26
During the past 13 years, Sartorius AG's highest Days Payable was 97.52. The lowest was 63.76. And the median was 78.48.
SARTF's Days Payable is ranked worse than 51.95% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs SARTF: 66.26
Sartorius AG's Days Payable
declined
from Mar. 2025 (69.94) to Mar. 2026 (65.23).
It may suggest that Sartorius AGaccelerated paying its suppliers.
Sartorius AG Days Payable Related Terms
Sartorius AG Days Payable Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sartorius AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a Days Payable of 65.23 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sartorius AG and its competitors. This is 17% below median its historical median of 78.48. Over the past decade, Sartorius AG's Days Payable has ranged from 63.76 to 97.52. According to the industry distribution chart, Sartorius AG ranks #413 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 51.9%.
Is Sartorius AG's Days Payable too high?
Sartorius AG's current Days Payable of 65.23 is 17% below median its 10-year median of 78.48. Over the past 10 years, this metric has ranged from a low of 63.76 to a high of 97.52. The Medical Devices & Instruments industry median Days Payable is 67.87. Sartorius AG's value of 65.23 is 3.9% below this industry median. Based on the distribution chart, Sartorius AG ranks #413 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #413 out of 795 companies for Days Payable. This places Sartorius AG in the lower half of its industry. The industry median Days Payable is 67.87. Sartorius AG's value of 65.23 is 3.9% below this benchmark. Historically, Sartorius AG's own Days Payable has ranged from 63.76 to 97.52 over the past decade. While the company's 10-year median is 78.48 vs. the industry median of 67.87, Sartorius AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Days Payable of 65.23 is 3.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Days Payable is 65.23, which is 17% below median its own 10-year median of 78.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current Days Payable is 65.23, which is 17% below median its 10-year median of 78.48 and 3.9% below the Medical Devices & Instruments industry median of 67.87. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Days Payable is 65.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
Days Payable: 65.23 (17% below median its 10-year median of 78.48)
GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
Industry Position: 3.9% below the Medical Devices & Instruments median (#413 of 795)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
